HCPCS Level II · Drugs administered other than oral method
J0215Injection, alefacept, 0.5 mg
Terminated 12/31/2025
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J0215
J0215 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, alefacept, 0.5 mg.
It was added to HCPCS effective 01/01/2004, and its current record took effect 01/01/2026.
It was terminated on 12/31/2025 and can't be billed for later dates of service.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Alefacept
- Date added
- 01/01/2004
- Action effective
- 01/01/2026
- Termination date
- 12/31/2025
- BETOS
- O1E
Related J02xx codes
- J0202Injection, alemtuzumab, 1 mg
- J0206Injection, allopurinol sodium, 1 mg
- J0207Injection, amifostine, 500 mg
- J0208Injection, sodium thiosulfate (pedmark), 100 mg
- J0209Injection, sodium thiosulfate (hope), 100 mg
- J0210Injection, methyldopate hcl, up to 250 mg
- J0211Injection, sodium nitrite 3 mg and sodium thiosulfate 125 mg (nithiodote)
- J0216Injection, alfentanil hydrochloride, 500 micrograms
- J0217Injection, velmanase alfa-tycv, 1 mg
- J0218Injection, olipudase alfa-rpcp, 1 mg
- J0219Injection, avalglucosidase alfa-ngpt, 4 mg
- J0220Injection, alglucosidase alfa, 10 mg, not otherwise specified
Common questions about J0215
Is HCPCS J0215 still valid?
- No. J0215 was terminated on 12/31/2025.
Does Medicare cover J0215?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.